GLPwatch
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
NCT01455857 · Completed
Last updated 2026-05-28This clinical trial tested ITCA 650, a new medication, in adults with type 2 diabetes to see how it affects their blood sugar levels over time.
Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 460 people
Who can join Ages 18–80 · all sexes
Timeline Started 2013-03 · est. completion 2014-09
Where 121 sites · United States
What this study is testing ClinicalTrials.gov NCT01455857 ↗
Description as written by the study sponsor.
Phase 3 study to examine whether treatment with ITCA-650 60 mcg/day or 40 mcg/day is superior to placebo when added to current therapy in reducing HbA1c in patients with type 2 diabetes.
Treatments tested
- ITCA 650 Drug
ITCA 650 is exenatide in DUROS
- ITCA placebo Other
Formulation in DUROS (no exenatide)
| Main thing measured | Change in HbA1c |
|---|---|
| Sponsor | Intarcia Therapeutics |
| Conditions studied | Type 2 Diabetes |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01455857 ↗